Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr:28:49-56.
doi: 10.1016/j.semcdb.2014.03.005. Epub 2014 Mar 12.

Epiregulin: roles in normal physiology and cancer

David J Riese 2nd  1 , Richard L Cullum  2
Affiliations
Review

Epiregulin: roles in normal physiology and cancer

David J Riese 2nd et al. Semin Cell Dev Biol. 2014 Apr.

Abstract

Epiregulin is a 46-amino acid protein that belongs to the epidermal growth factor (EGF) family of peptide hormones. Epiregulin binds to the EGF receptor (EGFR/ErbB1) and ErbB4 (HER4) and can stimulate signaling of ErbB2 (HER2/Neu) and ErbB3 (HER3) through ligand-induced heterodimerization with a cognate receptor. Epiregulin possesses a range of functions in both normal physiologic states as well as in pathologic conditions. Epiregulin contributes to inflammation, wound healing, tissue repair, and oocyte maturation by regulating angiogenesis and vascular remodeling and by stimulating cell proliferation. Deregulated epiregulin activity appears to contribute to the progression of a number of different malignancies, including cancers of the bladder, stomach, colon, breast, lung, head and neck, and liver. Therefore, epiregulin and the elements of the EGF/ErbB signaling network that lie downstream of epiregulin appear to be good targets for therapeutic intervention.

Keywords: EGF/ErbB receptors; Epiregulin; Epithelial cell proliferation; Inflammation; Oocyte maturation; Tumor Progression.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Regulation of tumor cell behavior by the epiregulin/EGF receptor signaling pathway is depicted.
See this image and copyright information in PMC

References

    1. Lim H, Dey SK, Das SK. Differential expression of the erbB2 gene in the periimplantation mouse uterus: potential mediator of signaling by epidermal growth factor-like growth factors. Endocrinology. 1997;138:1328–37. - PubMed
    1. Normanno N, Bianco C, De Luca A, Salomon DS. The role of EGF-related peptides in tumor growth. Front Biosci. 2001;6:D685–707. - PubMed
    1. Ocana A, Pandiella A. Targeting HER receptors in cancer. Current pharmaceutical design. 2013;19:808–17. - PubMed
    1. Patel R, Leung HY. Targeting the EGFR-family for therapy: biological challenges and clinical perspective. Current pharmaceutical design. 2012;18:2672–9. - PubMed
    1. Riese DJ., 2nd Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery? Expert opinion on drug discovery. 2011;6:185–93. - PMC - PubMed

Publication types